FDA Approves Truqap Plus Faslodex for Advanced HR-Positive Breast Cancer

The FDA has approved AstraZeneca’s capivasertib (Truqap) plus fulvestrant (Faslodex) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1 or PTEN biomarker alterations.